1-苄基-3-甲氧基-1H-吲唑 | 4454-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-苄基-3-甲氧基-1H-吲唑
• 英文名称: 1-benzyl-3-methoxy-1H-indazole
• 英文别名: 1-Benzyl-3-methoxy-1H-indazol；1-benzyl-3-methoxyindazole
• CAS: 4454-33-5
• 化学式: C₁₅H₁₄N₂O
• 分子量: 238.289
• InChiKey: WKRXNLHIWBMTPM-UHFFFAOYSA-N

物化性质

• 沸点：
  138 °C(Press: 0.5 Torr)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  苄达酸 在 2,4,6-三甲基吡啶 、 ammonium peroxydisulfate 、 1,4-环己二烯 作用下， 以 氘代二甲亚砜 为溶剂， 反应 2.0h， 以52%的产率得到1-苄基-3-甲氧基-1H-吲唑
  参考文献：
  名称：

  脂肪族羧酸的直接加氢脱羧：无金属和无光

  摘要：

  已经开发了一种用于脂肪族羧酸直接加氢脱羧的温和且廉价的方法。该反应不需要金属、光或催化剂，使该协议操作简单、易于扩展且更具可持续性。至关重要的是，在大多数情况下不需要额外的 H 原子源，同时观察到广泛的底物范围和官能团耐受性。

  DOI：

  10.1021/acs.orglett.1c04079

文献信息

• HIGH PENETRATION COMPOSITIONS AND USES THEREOF
  申请人：Yu Chongxi

  公开号：US20090238763A1

  公开（公告）日：2009-09-24

  The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

  本发明涉及新型高渗透性组合物或高渗透性前药（HPP）的组成和用途，特别是用于非甾体抗炎药（NSAIAs）的HPP，其能够高效地穿过生物屏障。这里的HPP能够在穿过生物屏障后转化为父活性药物或药物代谢物，从而可以治疗与父药物或代谢物相关的疾病。此外，由于能够穿过生物屏障，这里的HPP能够到达父药物可能无法进入或无法在目标区域产生足够浓度的区域，从而提供新的治疗方法。这里的HPP可以通过各种给药途径给予受试者。例如，由于其穿透生物屏障的能力，HPP可以在局部给药到疾病作用部位并以高浓度存在，从而避免系统性给药的需要。另一个例子是，这里的HPP可以被系统性地给药到生物体内，并以更快的速率进入循环系统。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093671A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝酰化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，并且描述了至少包含一种亚硝酰化NSAID和可选的至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性内皮源性松弛因子的水平或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性内皮源性松弛因子的水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID，可选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防使用非甾体抗炎化合物导致的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION
  申请人：Glenn Jeffrey S.

  公开号：US20120148534A1

  公开（公告）日：2012-06-14

  Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

  简单地说，本公开的实施例包括化合物、药物组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3'UTR结合的方法、治疗宿主肝纤维化的方法等。
• Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use
  申请人：Earl Richard

  公开号：US20110098253A1

  公开（公告）日：2011-04-28

  The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

  该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防非甾体类抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的新组合物的给药方法，该组合物包括至少一种硝化的非甾体类抗炎药，以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂。
• POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ARYL- AND HETEROARYLACETIC ACIDS WITH VERY FAST SKIN PENETRATION RATE
  申请人：Techfields Biochem Co. Ltd

  公开号：EP2990402A1

  公开（公告）日：2016-03-02

  The novel positively charged pro-drugs of aryl- and heteroarylacetic acids in the general formula(1) 'Structure 1' were designed and synthesized. The compounds of the general formula(1) 'Structure 1' indicated above can be prepared from functional derivatives of tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, 6MNA, ibufenac, and related compounds, (for example acid halides or mixed anhydrides), by reaction with suitable alcohols, thiols, or amines. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin ∼100 times faster than does tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, or related compounds. It takes 2-4 hours for tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, 6MNA, ibufenac, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about 40-50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of the prodrug enables tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, 6MNA, ibufenac, and related compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of NSAIAs. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.

  设计并合成了通式(1) "结构 1 "的新型芳基和杂芳基乙酸带正电的原药。上述通式(1)'结构 1'的化合物可由托美丁、左美吡拉、依托度酸、氨非那酸、溴非那酸、阿洛芬酸、芬氯芬酸、阿西美辛、吲哚美辛、舒林达、吲哚美辛的功能性衍生物制备、吲哚美辛、舒林达克、芬妥拉克、洛那唑拉克、苯达拉克、6MNA、依布芬酸及相关化合物（例如酸卤化物或混合酸酐），与适当的醇、硫醇或胺反应。这些原药带正电荷的氨基不仅在很大程度上增加了药物的溶解度，而且还与膜上磷酸头基的负电荷结合，将原药推入细胞质中。结果表明，原药在人体皮肤中的扩散速度比托美丁、佐美吡拉克、依托度酸、氨非那酸、溴非那酸、阿氯芬酸、芬氯芬酸、阿西美辛、吲哚美辛、舒林达克、芬妥扎酸、洛那唑酸、苯达扎酸或相关化合物快 100 倍。口服托美丁、佐美吡拉克、依托度酸、阿芬酸、溴芬酸、阿氯芬酸、芬氯芬酸、乙酰美沙星、吲哚美辛、舒林达克、芬妥扎克、洛那唑拉克、苯达沙克、6MNA、依布芬酸和相关化合物需要 2-4 小时才能达到血浆峰值水平，但这些原药经皮服用后只需 40-50 分钟就能达到血浆峰值水平。在血浆中，90% 以上的原药可在几分钟内变回药物。这些原药可用于治疗人类或动物的任何非甾体抗炎药物可治疗的疾病。原药不仅可以口服，还可以透皮给药，用于任何类型的医疗，并可避免非甾体抗炎药的大部分副作用，尤其是消化道紊乱，如消化不良、胃十二指肠出血、胃溃疡和胃炎。原药的可控透皮给药系统可使托美丁、佐美吡拉克、依托度酸、氨非那酸、溴非那酸、阿氯芬酸、芬氯芬酸、阿西美辛、吲哚美辛、舒林达克、芬妥扎克、洛那唑拉克、苯达扎克、6MNA、依布芬酸和相关化合物不断达到最佳治疗血药浓度，从而提高疗效并减少非甾体抗炎药的副作用。这些原药透皮给药的另一大好处是，用药（尤其是给儿童用药）将变得更加容易。